Popp, AlbrechtAlbrechtPopp0000-0002-5954-7495Varathan, NadshathraNadshathraVarathanBuffat, HeleneHeleneBuffatSenn, ChristophChristophSennPerrelet, RomainRomainPerreletLippuner, KurtKurtLippuner2024-10-072024-10-072018-07https://boris-portal.unibe.ch/handle/20.500.12422/61324The aim of the present study was to document the changes in bone mineral density (BMD) 1 year after denosumab loss-of-effect following long-term treatment with subcutaneous denosumab 60 mg Q6M during 7 or 10 years and in the absence of any treatment with a bone active substance. All postmenopausal women with osteoporosis who participated to the randomized placebo-controlled FREEDOM core trial and its open-label extension at the University Hospital of Bern, Switzerland, and who accepted to undergo off-treatment follow-up during 1 year after discontinuation, were included (N = 12). After 10 years of denosumab, mean lumbar spine (LS) BMD had increased by 21.2% vs. baseline. One year after discontinuation LS BMD had decreased by - 9.1% vs. Year 10, resulting in a net gain of 10.2% vs. baseline. At total hip (TH) and femoral neck (FN), BMD had increased by 8.3 and 8.1% in Year 10 vs. baseline, respectively. 1 Year after discontinuation, BMD had decreased by - 12.7 and - 11.0% vs. Year 10, respectively, corresponding to net BMD losses of - 5.5 and - 3.8% vs. baseline, respectively. Similar albeit less pronounced changes were observed in those treated with denosumab during 7 years. Stopping denosumab after long-term exposure resulted in BMD losses of large order of magnitude at all measured sites, suggesting that treatment duration may predict the rate and amount of bone lost.enBone mineral density Denosumab Long-term therapy Osteoporosis Rebound-associated bone loss600 - Technology::610 - Medicine & healtharticle10.7892/boris.1222352938001310.1007/s00223-018-0394-4